ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for smarter Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.
Daiichi Sankyo Co Ltd (PK)

Daiichi Sankyo Co Ltd (PK) (DSKYF)

25.25
-0.66
(-2.55%)
Closed February 08 3:00PM

Professional-Grade Tools, for Individual Investors.

Key stats and details

Current Price
25.25
Bid
24.29
Ask
27.49
Volume
11,161
24.35 Day's Range 26.95
23.67 52 Week Range 44.64
Market Cap
Previous Close
25.91
Open
26.79
Last Trade
605
@
25.25
Last Trade Time
Financial Volume
US$ 280,376
VWAP
25.121
Average Volume (3m)
56,966
Shares Outstanding
1,916,787,029
Dividend Yield
17,987.70%
PE Ratio
0.24
Earnings Per Share (EPS)
104.72
Revenue
1.63T
Net Profit
200.73B

About Daiichi Sankyo Co Ltd (PK)

Sector
Pharmaceutical Preparations
Industry
Pharmaceutical Biolog/vaccines
Headquarters
Chuo, Tokyo, Jpn
Founded
2005
Daiichi Sankyo Co Ltd (PK) is listed in the Pharmaceutical Preparations sector of the OTCMarkets with ticker DSKYF. The last closing price for Daiichi Sankyo (PK) was US$25.91. Over the last year, Daiichi Sankyo (PK) shares have traded in a share price range of US$ 23.67 to US$ 44.64.

Daiichi Sankyo (PK) currently has 1,916,787,029 shares outstanding. The market capitalization of Daiichi Sankyo (PK) is US$49.66 billion. Daiichi Sankyo (PK) has a price to earnings ratio (PE ratio) of 0.24.

DSKYF Latest News

Daiichi Sankyo's Once-Daily Lixiana® (edoxaban) Approved for the Prevention of Stroke and Systemic Embolism in Non-Valvular ...

Daiichi Sankyo's Once-Daily Lixiana® (edoxaban) Approved for the Prevention of Stroke and Systemic Embolism in Non-Valvular Atrial Fibrillation and for the Treatment and Prevention of Recurrent...

Daiichi Sankyo, Inc. and Asubio Pharmaceuticals, Inc. Merge

Daiichi Sankyo, Inc. and Asubio Pharmaceuticals, Inc. Merge PR Newswire PARSIPPANY, N.J., April 1, 2015 PARSIPPANY, N.J., April 1, 2015 /PRNewswire/ -- Daiichi Sankyo, Inc., the US subsidiary of...

Venue Change

Tue, Oct 08, 2013 12:00 - Daiichi Sankyo Co., Ltd. (DSKYF: OTC Link) - Venue Change - The symbol, DSKYF, no longer trades on Grey Market. As of Tue, Oct 08, 2013, DSKYF trades on OTC Link. You...

Glaxo Files for Two Flu Vaccines - Analyst Blog

Recently, GlaxoSmithKline (GSK) announced that it has filed marketing applications for two influenza vaccines. The vaccines, up for approval, include a quadrivalent influenza vaccine for the...

Glaxo and Daiichi to Set Up JV - Analyst Blog

British drugmaker GlaxoSmithKline (GSK) recently announced that it has signed an agreement with Daiichi Sankyo (DSKYF) to form a joint venture (JV). The JV will be called Japan Vaccine Co., Ltd...

Daiichi Sankyo, Inc. Names Danesha Dixon Smith Vice President of Human Resources

Daiichi Sankyo, Inc. Names Danesha Dixon Smith Vice President of Human Resources PR Newswire PARSIPPANY, N.J., June 28, 2011 PARSIPPANY, N.J., June 28, 2011 /PRNewswire/ -- Daiichi Sankyo, Inc...

John P. Gargiulo Named President and CEO of Daiichi Sankyo, Inc.

John P. Gargiulo Named President and CEO of Daiichi Sankyo, Inc. PR Newswire PARSIPPANY, N.J., April 4, 2011 PARSIPPANY, N.J., April 4, 2011 /PRNewswire/ -- Daiichi Sankyo, Inc. (DSI) announced...

Update: Daiichi Sankyo Completes Enrollment of the Edoxaban Global Phase III ENGAGE AF-TIMI 48 Study in Patients With Atrial Fib

Update: Daiichi Sankyo Completes Enrollment of the Edoxaban Global Phase III ENGAGE AF-TIMI 48 Study in Patients With Atrial Fibrillation - More Than 21,000 Patients Enrolled in the Largest...

Daiichi Sankyo Completes Enrollment of the Edoxaban Global Phase III ENGAGE AF-TIMI 48 Study in Patients With Atrial Fibrillatio

Daiichi Sankyo Completes Enrollment of the Edoxaban Global Phase III ENGAGE AF-TIMI 48 Study in Patients With Atrial Fibrillation - More Than 21,000 Patients Enrolled in the Largest Clinical...

ArQule and Daiichi Sankyo Expand Drug Discovery Collaboration in Oncology

ArQule and Daiichi Sankyo Expand Drug Discovery Collaboration in Oncology PR Newswire WOBURN, Massachusetts, October 12, 2010 WOBURN, Massachusetts, October 12, 2010 /PRNewswire/ -- ArQule, Inc...

PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
1-1.86-6.8609369236427.1130.1223.671907426.11379836CS
4-2.49-8.9762076423927.7430.623.6712919226.99584382CS
12-3.21-11.278988053428.4634.7523.675696627.1777302CS
26-14.59-36.621485943839.8444.6423.672659427.69389006CS
52-6.19-19.688295165431.4444.6423.672146029.2411054CS
1565.2826.439659489219.9744.6419.761184829.29699677CS
260-47.67-65.373011519572.9295.9617.61869429.13429269CS

DSKYF - Frequently Asked Questions (FAQ)

What is the current Daiichi Sankyo (PK) share price?
The current share price of Daiichi Sankyo (PK) is US$ 25.25
How many Daiichi Sankyo (PK) shares are in issue?
Daiichi Sankyo (PK) has 1,916,787,029 shares in issue
What is the market cap of Daiichi Sankyo (PK)?
The market capitalisation of Daiichi Sankyo (PK) is USD 49.66B
What is the 1 year trading range for Daiichi Sankyo (PK) share price?
Daiichi Sankyo (PK) has traded in the range of US$ 23.67 to US$ 44.64 during the past year
What is the PE ratio of Daiichi Sankyo (PK)?
The price to earnings ratio of Daiichi Sankyo (PK) is 0.24
What is the cash to sales ratio of Daiichi Sankyo (PK)?
The cash to sales ratio of Daiichi Sankyo (PK) is 0.03
What is the reporting currency for Daiichi Sankyo (PK)?
Daiichi Sankyo (PK) reports financial results in JPY
What is the latest annual turnover for Daiichi Sankyo (PK)?
The latest annual turnover of Daiichi Sankyo (PK) is JPY 1.63T
What is the latest annual profit for Daiichi Sankyo (PK)?
The latest annual profit of Daiichi Sankyo (PK) is JPY 200.73B
What is the registered address of Daiichi Sankyo (PK)?
The registered address for Daiichi Sankyo (PK) is 3-5-1 NIHONBASHI-HONCHO, CHUO-KU, CHUO, TOKYO, 103-8426
What is the Daiichi Sankyo (PK) website address?
The website address for Daiichi Sankyo (PK) is www.daiichisankyo.co.jp
Which industry sector does Daiichi Sankyo (PK) operate in?
Daiichi Sankyo (PK) operates in the PHARMACEUTICAL BIOLOG/VACCINES sector

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
SHWZMedicine Man Technologies Inc (CE)
US$ 0.0011
(109,900.00%)
530
ZHCLFZenith Capital Corporation (CE)
US$ 0.10
(99,900.00%)
6k
GNCAQGenocea Biosciences Inc (CE)
US$ 0.0005
(49,900.00%)
2k
CCTLCoin Citadel (PK)
US$ 0.0002
(19,900.00%)
509.6k
TPTWTPT Global Tech Inc (CE)
US$ 0.0002
(19,900.00%)
25.08M
BRGOBergio International Inc (PK)
US$ 0.000001
(-99.00%)
502k
POLCQPolished Inc (CE)
US$ 0.000001
(-99.00%)
130
PUGEPuget Technologies Inc (CE)
US$ 0.000001
(-99.00%)
169k
COSGCosmos Group Holdings Inc (PK)
US$ 0.000001
(-99.00%)
10M
RNWFRenewal Fuels Inc (CE)
US$ 0.000001
(-99.00%)
133
IMTLImage Protect Inc (PK)
US$ 0.0001
(-33.33%)
289.87M
ABQQAB International Group Corporation (PK)
US$ 0.0003
(-25.00%)
286.78M
PDGOParadigm Oil and Gas Inc (PK)
US$ 0.0001
(0.00%)
225.08M
BOMObowmo Inc (PK)
US$ 0.0005
(66.67%)
211.25M
RONNRonn Motor Group Inc (PK)
US$ 0.0003
(0.00%)
187.29M